A new study published in Acta Pharmaceutica Sinica B finds that cannabidiol (CBD) may directly counteract the effects of methamphetamine (METH) addiction by targeting a key protein in brain energy regulation.
Researchers from the First Hospital of Jilin University, Shandong First Medical University, the University of Science and Technology of China, and several other institutions found that CBD reduced behaviors linked to METH use, including locomotor sensitization and conditioned place preference. The study also reported that CBD alleviated damage caused by METH at the cellular level, such as loss of cristae, reduced ATP production, and declines in membrane potential.
The team identified ATP5A1, a subunit of ATP synthase, as a direct molecular target of CBD.
According to the abstract, “CBD demonstrated the ability to ameliorate METH-induced ubiquitination of ATP5A1 via the D376 residue, thereby reversing the METH-induced reduction of ATP5A1 and promoting the assembly of ATP synthase.” This interaction appeared to restore energy balance in brain cells while reducing addictive behaviors.
Further testing showed that blocking ATP signaling pathways—including pannexin 1, CD39, and the adenosine A1 receptor—diminished CBD’s therapeutic benefits. In addition, silencing ATP5A1 in the ventral tegmental area reversed CBD’s protective effects against METH addiction.
The findings suggest that CBD helps regulate the ATP5A1-adenosine A1 receptor (A1R) signaling pathway to mitigate the neurological and behavioral effects of methamphetamine. While the research remains preclinical, it offers strong evidence that ATP5A1 could serve as a novel therapeutic target in the treatment of stimulant addiction.
